{"id":646537,"date":"2023-04-11T18:30:01","date_gmt":"2023-04-11T18:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=646537"},"modified":"2023-04-11T18:30:01","modified_gmt":"2023-04-11T18:30:01","slug":"hearing-loss-clinical-trials-2023-updates-fda-approvals-therapies-treatment-market-and-companies-by-delveinsight-sensorion-pipeline-therapeutics-frequency-therapeutics-otonomy-inc","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hearing-loss-clinical-trials-2023-updates-fda-approvals-therapies-treatment-market-and-companies-by-delveinsight-sensorion-pipeline-therapeutics-frequency-therapeutics-otonomy-inc_646537.html","title":{"rendered":"Hearing Loss Clinical Trials 2023 (Updates): FDA Approvals, Therapies, Treatment Market and Companies by DelveInsight | Sensorion, Pipeline Therapeutics, Frequency Therapeutics, Otonomy, Inc."},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1681212804.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hearing Loss Clinical Trials 2023 (Updates): FDA Approvals, Therapies, Treatment Market and Companies by DelveInsight | Sensorion, Pipeline Therapeutics, Frequency Therapeutics, Otonomy, Inc.\" src=\"https:\/\/www.abnewswire.com\/uploads\/1681212804.jpeg\" alt=\"Hearing Loss Clinical Trials 2023 (Updates): FDA Approvals, Therapies, Treatment Market and Companies by DelveInsight | Sensorion, Pipeline Therapeutics, Frequency Therapeutics, Otonomy, Inc.\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Hearing Loss Clinical Trials<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s hearing loss pipeline report depicts a robust space with 35+ active hearing loss companies working to develop 45+ pipeline therapies for hearing loss treatment.<\/div>\n<p style=\"text-align: justify;\">(Albany, USA) DelveInsight&rsquo;s&nbsp;<strong>&#8216;Hearing Loss Pipeline Insight 2023&#8217;<\/strong>&nbsp;report provides comprehensive global coverage of available, marketed, and pipeline hearing loss therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the hearing loss pipeline domain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more in detail about the Hearing Loss Pipeline Report offering, click here @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hearing-loss-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Hearing Loss Pipeline Assessment<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Hearing Loss Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s hearing loss pipeline report depicts a robust space with<strong>&nbsp;35+&nbsp;<\/strong>active players working to develop&nbsp;<strong>45+&nbsp;<\/strong>pipeline therapies for hearing loss treatment.&nbsp;<\/li>\n<li>leading hearing loss companies working in the treatment market are&nbsp;<strong>Sensorion, Pipeline Therapeutics, Frequency Therapeutics, Otonomy, Inc., Strekin AG, Heyu (Suzhou) Pharmaceutical Technology Co., Ltd, Sound Pharmaceuticals Incorporated, Novartis, Gateway Biotechnology, Inc., Decibel Therapeutics, Akouos, Acousia Therapeutics GmbH, AGTC, BridgeBio Inc., Lineage Cell Therapeutics, Inc., Rinri Therapeutics Ltd., Autifony Therapeutics, AudioCure Pharma GmbH, Anida Pharma Inc., Mogrify, Astellas Pharma Inc., Altamira Therapeutics, Myrtelle, Hoba Therapeutics, Perha Pharmaceuticals,&nbsp;&nbsp;<\/strong>and others.<\/li>\n<li>Some of the hearing loss drugs in different phases of development are&nbsp;<strong>PIPE 505, FX-322, SENS-401, OTO-413, STR001, HY01, SPI-1005, CGF166, Zonisamide, DB-OTO, AAV.103, AAV.104, DB-020, AK-OTOF, ACOU085, ACOU082, OTO-825, OTO-6XX, OTO-510, ,BBP-815, FX-345, Auditory Neuronal Cell Therapy, AC102,&nbsp; AP-001,&nbsp; AM-111, HB-097,&nbsp;<\/strong>and others are under different phases of hearing loss clinical trials.<\/li>\n<li>In September 2022,&nbsp;<strong>Sensorion<\/strong>&nbsp;announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) had adopted a positive opinion on Sensorion&rsquo;s application for Orphan Drug Designation (ODD) for its lead therapy gene candidate,&nbsp;<strong>OTOF-GT<\/strong>, a gene therapy intended for the treatment of otoferlin gene mediated hearing loss.&nbsp;<\/li>\n<li>In September 2022,&nbsp;<strong>Decibel Therapeutics<\/strong>&nbsp;announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1\/2 clinical trial in pediatric patients of&nbsp;<strong>DB-OTO<\/strong>, a gene therapy product candidate designed to provide durable restoration of hearing in individuals with profound congenital hearing loss due to an otoferlin deficiency.<\/li>\n<li>In July 2022,&nbsp;<strong>Mogrify Limited<\/strong>&nbsp;and&nbsp;<strong>Astellas Pharma Inc.&nbsp;<\/strong>announced that they had executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.<\/li>\n<li>In May 2022,&nbsp;<strong>Acousia Therapeutics GmbH announced&nbsp;<\/strong>that it would present data on the company&rsquo;s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit to be held in person in Boston (MA) from June 20&ndash;23, 2022.ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in hearing loss treatment drugs @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hearing-loss-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr%20\"><strong>https:\/\/www.delveinsight.com\/sample-request\/hearing-loss-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hearing Loss Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Hearing loss is a very common medical condition that increases in frequency and severity with age. The affected population is also large, ranging from newborns to elderly patients, and is nearly universal in the 70+ age group. Sound waves arriving at the auricle, passing through the external auditory canal (EAC), and causing a vibration of the tympanic membrane are all part of normal hearing function. The vibration is then transmitted to the cochlea via the ossicles (malleus, incus, and stapes).<\/p>\n<p style=\"text-align: justify;\">The most common hearing loss causes are auricle or helix abnormal formation, cerumen impaction, ear canal foreign bodies, otitis externa, ossicular chain dysfunction or fixation, and middle ear effusion. Muffling of speech and other sounds, trouble hearing consonants, avoidance of some social settings, and others are some of the common hearing loss symptoms.<\/p>\n<p style=\"text-align: justify;\">Several methods, such as physical examination, general screening tests, and audiometer tests, are the most common tests used for hearing loss diagnosis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about hearing loss treatment drugs @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hearing-loss-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr%20\"><strong>https:\/\/www.delveinsight.com\/sample-request\/hearing-loss-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hearing Loss Pipeline Drugs mentioned in the report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>STR001: Strekin<\/li>\n<li>FX 322: Frequency Therapeutics<\/li>\n<li>Arazasetron: Sensorion<\/li>\n<li>PIPE 505: Pipeline Therapeutics<\/li>\n<li>OTO 413: Otonomy<\/li>\n<li>DB OTO : Decibel Therapeutics<\/li>\n<li>And many others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging hearing loss pipeline therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hearing-loss-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr%20\">https:\/\/www.delveinsight.com\/sample-request\/hearing-loss-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hearing Loss Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">The&nbsp;hearing loss pipeline&nbsp;report proffers an integral view of the hearing loss emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Hearing Loss Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Hearing loss Therapeutic Assessment By Product Type:&nbsp;<\/strong>Mono, Combination, Mono\/Combination<\/li>\n<li><strong>Hearing loss Therapeutic Assessment By Clinical Stages:&nbsp;<\/strong>Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li><strong>Hearing loss Therapeutics Assessment<\/strong>&nbsp;<strong>By Route of Administration:<\/strong>&nbsp;Oral, Intratympanic<\/li>\n<li><strong>Hearing loss Therapeutics Assessment<\/strong>&nbsp;<strong>By Molecule Type<\/strong>: Oligonucleotide, Peptide, Small molecule<\/li>\n<li><strong>Hearing loss Therapeutics Assessment<\/strong>&nbsp;<strong>By Mechanism of Action:&nbsp;<\/strong>Amyloid precursor protein secretase inhibitors, Stem cell stimulants, Calcineurin inhibitors, Serotonin 3 receptor antagonists, Brain derived neurotrophic factor agonists, Peroxisome proliferator-activated receptor gamma agonists, Gene transference, OTOF protein expression stimulants<\/li>\n<li><strong>Key Hearing Loss Companies<\/strong>: Sensorion, Pipeline Therapeutics, Frequency Therapeutics, Otonomy, Inc., Strekin AG, Heyu (Suzhou) Pharmaceutical Technology Co., Ltd, Sound Pharmaceuticals Incorporated, Novartis, Gateway Biotechnology, Inc., Decibel Therapeutics, Akouos, Acousia Therapeutics GmbH, AGTC, BridgeBio Inc., Lineage Cell Therapeutics, Inc., Rinri Therapeutics Ltd., Autifony Therapeutics, AudioCure Pharma GmbH, Anida Pharma Inc., Mogrify, Astellas Pharma Inc., Altamira Therapeutics, Myrtelle, Hoba Therapeutics, Perha Pharmaceuticals,&nbsp; and others<\/li>\n<li><strong>Key Hearing Loss Pipeline Therapies<\/strong>: PIPE 505, FX-322, SENS-401, OTO-413, STR001, HY01, SPI-1005, CGF166, Zonisamide, DB-OTO, AAV.103, AAV.104, DB-020, AK-OTOF, ACOU085, ACOU082, OTO-825, OTO-6XX, OTO-510, ,BBP-815, FX-345, Auditory Neuronal Cell Therapy, AC102,&nbsp; AP-001,&nbsp; AM-111, HB-097, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for hearing loss treatment, visit @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hearing-loss-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr%20\"><strong>https:\/\/www.delveinsight.com\/sample-request\/hearing-loss-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Hearing Loss Pipeline Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Hearing Loss Pipeline Report Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Hearing Loss Pipeline: Overview<\/p>\n<p style=\"text-align: justify;\">4. Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. Hearing Loss Clinical Trial Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. Hearing Loss Pipeline: Late Stage Products (Pre-registration)<\/p>\n<p style=\"text-align: justify;\">7. Hearing Loss Pipeline: Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">7.1. STR001: Strekin<\/p>\n<p style=\"text-align: justify;\">8. Hearing Loss Pipeline: Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">8.1. FX 322: Frequency Therapeutics<\/p>\n<p style=\"text-align: justify;\">9. Hearing Loss Pipeline: Early Stage Products (Phase I\/II)<\/p>\n<p style=\"text-align: justify;\">9.1. OTO 413: Otonomy<\/p>\n<p style=\"text-align: justify;\">10. Hearing Loss Pipeline Therapeutics Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products in the Hearing Loss Pipeline<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Key Hearing Loss Companies<\/p>\n<p style=\"text-align: justify;\">14. Key Products in the Hearing Loss Pipeline<\/p>\n<p style=\"text-align: justify;\">15. Hearing Loss Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16. Hearing Loss Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hearing-loss-clinical-trials-2023-updates-fda-approvals-therapies-treatment-market-and-companies-by-delveinsight-sensorion-pipeline-therapeutics-frequency-therapeutics-otonomy-inc\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hearing-loss-clinical-trials-2023-updates-fda-approvals-therapies-treatment-market-and-companies-by-delveinsight-sensorion-pipeline-therapeutics-frequency-therapeutics-otonomy-inc\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hearing Loss Clinical Trials DelveInsight\u2019s hearing loss pipeline report depicts a robust space with 35+ active hearing loss companies working to develop 45+ pipeline therapies for hearing loss treatment. (Albany, USA) DelveInsight&rsquo;s&nbsp;&#8216;Hearing Loss Pipeline Insight 2023&#8217;&nbsp;report provides comprehensive global coverage &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hearing-loss-clinical-trials-2023-updates-fda-approvals-therapies-treatment-market-and-companies-by-delveinsight-sensorion-pipeline-therapeutics-frequency-therapeutics-otonomy-inc_646537.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-646537","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/646537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=646537"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/646537\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=646537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=646537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=646537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}